Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease

被引:52
作者
Zhao, Yuhong [1 ,2 ]
Peng, Ran [1 ]
Zhao, Wang [1 ]
Liu, Qiong [1 ]
Guo, Yuan [1 ]
Zhao, Shuiping [1 ]
Xu, Danyan [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Internal Cardiovasc Med, Changsha 410399, Hunan, Peoples R China
[2] Affiliated Peace Changzhi Med Coll Hosp, Changzhi, Shanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
atorvastatin; cardiotrophin-1; cholesterol; high sensitive-C reactive protein; zhibitai; C-REACTIVE PROTEIN; ALL-CAUSE MORTALITY; HEART-DISEASE; RISK; STATINS; ATHEROSCLEROSIS; CARDIOTROPHIN-1; ASSOCIATION; POPULATION; PREVENTION;
D O I
10.1097/MD.0000000000006104
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Atorvastatin decreases blood lipids but is associated with side effects. Zhibitai is a traditional Chinese medicine used to treat blood lipid disorders. The objective of this study is to evaluate the lipid-lowering effect, antiinflammatory effect, and adverse events of zhibitai combined to atorvastatin in patients with coronary heart diseases (CHDs). Methods: Patients with CHD (n= 150) were randomized to: zhibitai 480mg+atorvastatin 10mg (ZA10 group), atorvastatin 20mg (A20 group), and atorvastatin 40mg (A40 group). Lipid profile, cardiotrophin-1 (CT-1), and C-reactive protein (CRP) were measured after 4 and 8 weeks of treatment. Self-reported side effects, liver function, kidney function, and creatine kinase levels were monitored. Results: After 8 weeks, triglycerides, total cholesterol (TC), LDL-cholesterol (LDL-C), and apolipoprotein B-100 (ApoB(100)) levels were decreased in the ZA10 group (-64%, -37%, -46%, and -54%, respectively, compared with baseline), and these changes were similar to those of the A40 group (P>0.05). CT-1 and high sensitivity-C reactive protein (hs-CRP) levels were significantly decreased in the ZA10 group after 4 and 8 weeks (4 weeks: -73% and 96%; 8 weeks: -89% and -98%; all P<0.01), without differences among the 3 groups (P>0.05). After 8 weeks of treatment, adverse events (abdominal distention, nausea, vomiting, and hunger) were found in 4, 5, and 7 patients in the ZA10, A20, and A40 groups, respectively. Conclusion: ZA10 significantly reduced triglycerides, TC, LDL-C, ApoB, CT-1, and hs-CRP levels in patients with CHD, similar to the effects of A40 and A20, but ZA10 lead to fewer adverse events. Abbreviations: CHD = coronary heart disease, ZA10 = zhibitai 480 mg + atorvastatin 10 mg, A20 = atorvastatin 20 mg, A40 = atorvastatin 40 mg, CT-1 = cardiotrophin-1, CRP = C-reactive protein, hs-CRP = high sensitivity-C reactive protein, TC = total cholesterol, LDL = low-density lipoprotein, LDL-C = LDL-cholesterol, ApoB100 = apolipoprotein B100, MI = myocardial infarction, CHM = Chinese herbal medicine.
引用
收藏
页数:6
相关论文
共 34 条
[1]  
Adams SP, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD010254.pub2, 10.1002/14651858.CD008226.pub2]
[2]  
[Anonymous], 2004, GLOB STRAT DIET PHYS
[3]   High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese - The Hisayama study [J].
Arima, Hisatomi ;
Kubo, Michiaki ;
Yonemoto, Koji ;
Doi, Yasufumi ;
Ninomiya, Toshiharu ;
Tanizaki, Yumihiro ;
Hata, Jun ;
Matsumura, Kiyoshi ;
Iida, Mitsuo ;
Kiyohara, Yutaka .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (07) :1385-1391
[4]   Effects of statins on nonlipid serum markers associated with cardiovascular disease - A systematic review [J].
Balk, EM ;
Lau, J ;
Goudas, LC ;
Jordan, HS ;
Kupelnick, B ;
Kim, LU ;
Karas, RH .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (08) :670-682
[5]   Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review [J].
Benn, Marianne .
ATHEROSCLEROSIS, 2009, 206 (01) :17-30
[6]  
Blair SN, 2009, BRIT J SPORT MED, V43, P1
[7]   Novel insights into the role of cardiotrophin-1 in cardiovascular diseases [J].
Calabro, P. ;
Limongelli, G. ;
Riegler, L. ;
Maddaloni, V. ;
Palmieri, R. ;
Golia, E. ;
Roselli, T. ;
Masarone, D. ;
Pacileo, G. ;
Golino, P. ;
Calabro, R. .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2009, 46 (02) :142-148
[8]   Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension [J].
Choi, H ;
Cho, DH ;
Shin, HH ;
Park, JB .
CIRCULATION JOURNAL, 2004, 68 (04) :297-303
[9]   2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease [J].
Fihn, Stephan D. ;
Blankenship, James C. ;
Naidu, Srihari S. ;
Ohman, E. Magnus ;
Smith, Peter K. ;
Alexander, Karen P. ;
Bittl, John A. ;
Byrne, John G. ;
Fletcher, Barbara J. ;
Fonarow, Gregg C. ;
Lange, Richard A. ;
Levine, Glenn N. ;
Maddox, Thomas M. ;
Anderson, Jeffrey L. ;
Halperin, Jonathan L. ;
Albert, Nancy M. ;
Bozkurt, Biykem ;
Brindis, Ralph G. ;
Curtis, Lesley H. ;
DeMets, David ;
Guyton, Robert A. ;
Hochman, Judith S. ;
Kovacs, Richard J. ;
Pressler, Susan J. ;
Sellke, Frank W. ;
Shen, Win-Kuang .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (18) :1929-1949
[10]  
Fihn SD, 2012, J AM COLL CARDIOL, V60, pE44, DOI 10.1016/j.jacc.2012.07.013